A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Biological Activity of SAR405838 in Patients With Advanced Cancer

Trial Profile

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Biological Activity of SAR405838 in Patients With Advanced Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs SAR 405838 (Primary)
  • Indications Liposarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Aug 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
    • 10 Aug 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 17 May 2017 Planned End Date changed from 1 Dec 2016 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top